The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mind-nrg.com

Stage

Series B | Alive

Total Raised

$10M

Last Raised

$8M | 9 yrs ago

About Mind-NRG

Mind-NRG is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood-brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 is being developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia.

Mind-NRG Headquarter Location

Rue de Jargonnant 2

Geneva, CH-1207,

Switzerland

+41 22 737 00 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Mind-NRG Patents

Mind-NRG has filed 7 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Neurological disorders
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/23/2019

10/27/2020

Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins

Grant

Application Date

5/23/2019

Grant Date

10/27/2020

Title

Related Topics

Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins

Status

Grant

Latest Mind-NRG News

Mind-NRG Closes €6M Series B Financing

Sep 4, 2013

By FinSMEs Mind-NRG , a Geneva, Switzerland-based company focusing on developing neuregulins to treat neurodegenerative diseases, closed its €6m (approximately $8m) Series B financing. Backers included new investor LRM and existing investor Index Ventures . Following the investment, Debora Dumont, Head of Health & Care at LRM will join the company’s board of directors. Created in 2010, Mind-NRG is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. In particular, it is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia. The company plans to use the funding to continue to develop NRG-101’s neuroprotective effect in Parkinson’s disease, with the aim of advancing the compound to proof-of-concept studies in patients. FinSMEs

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.